GGrantIndex
Sort

48,018 grants matching immunotherapy

Costimulation blockade, chimerism and tolerance across varying degrees of MHC dis

$744,915
Christian P Larsen · Emory University · U19 · FY2008 · AI

Epigenetic Regulation of Normal and Pathologic CTCF Functions by BORIS

$744,264
Victor Lobanenkov · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI

THERAPEUTIC COCAINE VACCINE

$744,249
Yale University · U19 · FY2000 · DA

Immune reconstitution following autologous and allogeneic stem cell transplant

$744,123
Frances Hakim · Division Of Basic Sciences - Nci · ZIC · FY2011 · CA

Development of highly neutralizing nanobodies against HIV-1 and SARS-CoV-2

$743,993
Rafael C Casellas · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2021 · AR

Longitudinal Immunological Impact of SARS-CoV-2 Infection

$743,919
Timothy Jensen Henrich · University Of California, San Francisco · R01 · FY2020 · AI

Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection

$743,809
Hatice Karauzum · Integrated Biotherapeutics, Inc. · R01 · FY2020 · AI

Allergen Loaded Nanoparticles for Food Allergy Tolerance

$743,761
Lonnie D Shea · University Of Michigan At Ann Arbor · R01 · FY2023 · AI

Epigenetic programing of CD4+ T cell proliferation, survival and function during chronic viral infection

$743,752
Jeffrey Scott Hale · Utah State Higher Education System--University Of Utah · R01 · FY2025 · AI

Targeting HIV-specific CAR T cells to the gut for the durable remission of HIV

$743,696
Pamela J Skinner · University Of Minnesota · R01 · FY2023 · DK

Winship National Clinical Trials Network Lead Academic Participating Site

$743,680
Kristin Higgins · Emory University · UG1 · FY2021 · CA

Defining & Characterizing Novel Mechanisms by which HIV-infected Primary CD4+ T-cells Intrinsically Resist Elimination by CTL

$743,679
R. Brad Jones · Weill Medical Coll Of Cornell Univ · R56 · FY2020 · AI

Production and Characterization of Human Immunoglobulin Producing Goats for Diagnostic Reagents and Therapeutics

$743,067
Hua Wu · Sab Capra, Llc · R42 · FY2020 · AI

Immune and transcriptomic biomarkers of progressive oral premalignant lesions

$743,064
Fatemeh Momen Heravi · Columbia University Health Sciences · U01 · FY2023 · DE

Hepatitis B Research Network (HBRN): Natural History and Treatment Studies

$742,927
Mandana Khalili · University Of California, San Francisco · U01 · FY2019 · DK

AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma

$742,887
Reeder McNeil Robinson · Leukogene Therapeutics, Inc. · R44 · FY2025 · CA

AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma

$742,887
Reeder McNeil Robinson · Leukogene Therapeutics, Inc. · R44 · FY2024 · CA

Quantifying the fitness cost of HIV-1 resistance to broadly neutralizing antibodies

$742,884
Rebecca Marie Lynch · George Washington University · R01 · FY2022 · AI

Ikaros regulation: study on hemo-lymphopoiesis

$742,864
Katia Georgopoulos · Massachusetts General Hospital · R01 · FY2025 · HL

Identification and eliminationof HIV reservoirs in oral lymphoid tissues by engineered NK cells.

$742,726
Jonathan Karn · Case Western Reserve University · R01 · FY2019 · DE

Development of botulinum neurotoxin immunotherapy, serotypes C, D, F, and G

$742,658
James D. Marks · University Of California, San Francisco · U01 · FY2008 · AI

01 Inflammation, Immunology and Immunotherapeutics Program

$742,500
Donald J Buchsbaum · University Of Alabama At Birmingham · P30 · FY2020 · CA

The role of the innate immune system on Treg reprogramming in human autoimmune di

$742,405
David A. Hafler · Yale University · U01 · FY2015 · AI

Modelling the dynamics of spontaneous clonal hematopoiesis in pet dogs during cancer therapy

$742,391
Cheryl A London · Tufts University Boston · R01 · FY2025 · CA

ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center

$742,329
Suresh S Ramalingam · Emory University · UG1 · FY2021 · CA